Efficacy of Nafamostat Mesilate for improving the performance of a bioartificial liver using porcine hepatocytes.
Our bioartificial liver (BAL) consists of porcine hepatocytes attached to beads and plasma perfused through the system. The function of our BAL lasts for approximately 7 hours. The objective of the present study was to investigate the efficacy of Nafamostat Mesilate (NM), a protease inhibitor and potent complement inhibitor, for improving the performance of the BAL. The experimental groups were divided as follows; the NM group (n=7) where the BAL had porcine hepatocytes with 3.8x10(-4) M, of NM, and the control group where the BAL had no NM. Plasma obtained from patients suffering from hepatic failure was perfused through the BAL for 10 hours. The viability of the porcine hepatocytes and the levels of alanine aminotransferase (ALT) in the human plasma were measured during perfusion. After the 10-hour perfusion, another human hepatic failure plasma was perfused for an additional 1 hour and then the function of the BAL was evaluated. After the 10-hour perfusion, the viability of the hepatocytes in the NM group was 51 +/- 7%, whereas that in the control group was rapidly reduced by 35 +/- 5%. Although the levels of ALT in the human plasma in both groups increased with the perfusion time, those in the NM group were significantly lower than those in the control group (p < 0.05). These results suggest that NM prevented damage to the porcine hepatocytes in human hepatic failure plasma as compared to the control group. In the human hepatic failure plasma before perfusion, the partial thrombin time (PT) and the plasma ammonia (NH3) levels were 19.8 +/- 12% and 288 +/- 102 microg/dl, respectively. Fischer's ratios were 0.98 +/- 0.39. Even after the 10-hour perfusion, the BAL in the NM group significantly improved the levels of PT (38 +/- 10%; p < 0.05), NH3 (214 +/- 34 microg/dl; p < 0.05) and Fischer's ratios (1.4 +/- 0.3; p < 0.05). On the other hand, the BAL in the control group did not show any improvement in those parameters. In conclusion, NM was found to help in maintaining the viability of porcine hepatocytes in human hepatic failure plasma, thereby allowing the porcine hepatocyte-based BAL to function much better.
Fujioka
H
H
Department of Surgery II, Nagasaki University School of Medicine, Japan.
Eguchi
S
S
Sugiyama
N
N
Kawazoe
Y
Y
Kawashita
Y
Y
Kamohara
Y
Y
Azuma
T
T
Furui
J
J
Kanematsu
T
T
D000410:Alanine Transaminase / Q000097:blood; D000641:Ammonia / Q000097:blood; D000818:Animals; D001550:Benzamidines; D002470:Cell Survival; D003169:Complement Inactivator Proteins / Q000494:pharmacology*; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008099:Liver / Q000166:cytology* / Q000187:drug effects*; D017093:Liver Failure / Q000097:blood / Q000628:therapy; D019164:Liver, Artificial; D011480:Protease Inhibitors / Q000494:pharmacology*; D013552:Swine; D013918:Thrombin Time
D001550:Benzamidines; D003169:Complement Inactivator Proteins; D006146:Guanidines; D011480:Protease Inhibitors; D000641:Ammonia; D000410:Alanine Transaminase; C032855:nafamostat